Placental Passage of Humulone and Protopine in an Ex Vivo Human Perfusion System.
Deborah SpiessVanessa Fabienne AbeggAntoine ChauveauAndrea TreyerMichael ReinehrMouhssin OufirElisa DuongOlivier PotteratMatthias HamburgerAna Paula Simões-WüstPublished in: Planta medica (2021)
The placental passage of humulone and protopine was investigated with a human ex vivo placental perfusion model. The model was first validated with diazepam and citalopram, 2 compounds known to cross the placental barrier, and antipyrine as a positive control. All compounds were quantified by partially validated U(H)PLC-MS/MS bioanalytical methods. Only a small portion of humulone initially present in the maternal circuit reached the fetal circuit. The humulone concentration in the maternal circuit rapidly decreased, likely due to metabolization in the placenta. Protopine was transferred from the maternal to the fetal circuit, with a steady-state reached after 90 min. None of the study compounds affected placental viability or functionality, as glucose consumption, lactate production, beta-human chorionic gonadotropin, and leptin release remained constant. Histopathological evaluation of all placental specimens showed unremarkable, age-appropriate parenchymal maturation with no pathologic findings.
Keyphrases
- endothelial cells
- ms ms
- induced pluripotent stem cells
- pluripotent stem cells
- birth weight
- pregnancy outcomes
- neoadjuvant chemotherapy
- magnetic resonance imaging
- contrast enhanced
- skeletal muscle
- high resolution
- metabolic syndrome
- insulin resistance
- weight loss
- liquid chromatography tandem mass spectrometry
- blood glucose
- atomic force microscopy
- simultaneous determination
- adipose tissue
- locally advanced
- gestational age
- high performance liquid chromatography
- fine needle aspiration